892494-07-4
892494-07-4 structure
- Name: ILS-920
- Chemical Name: ILS-920
- CAS Number: 892494-07-4
- Molecular Formula: C57H86N2O14
- Molecular Weight: 1023.30
- Catalog: Signaling Pathways Membrane Transporter/Ion Channel Calcium Channel
- Create Date: 2020-06-01 15:59:18
- Modify Date: 2024-01-02 20:08:46
-
ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin FKBP52 and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for FKBP52 versus FKBP12[1].
| Name | ILS-920 |
|---|
| Description | ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin FKBP52 and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for FKBP52 versus FKBP12[1]. |
|---|---|
| Related Catalog | |
| Target |
FKBP52[1] L-type voltage-gated calcium channels (VGCC)[1] |
| In Vitro | ILS-920 promotes neuronal survival and stimulates neurite outgrowth with potent neurotrophic activities in cortical neuronal cultures[1]. ILS-920 can inhibit L-type Ca2+ channels in rat hippocampal neurons and F-11 dorsal root ganglia (DRG)/neuroblastoma cells. ILS-920 can protect neurons from Ca2+-induced cell death by modulating Ca2+ channels and promote neurite outgrowth via FKBP52 binding[1]. |
| In Vivo | In a transient middle cerebral artery occlusion (tMCAO) model of ischemic stroke, ILS-920, administered 4 h postocclusion at 10 and 30 mg/kg, significantly reduces infarct volume by 24% and 23% in 72 h, respectively, and robustly enhances functional recovery measured by improvement in neurological deficits[1]. |
| References |
| Molecular Formula | C57H86N2O14 |
|---|---|
| Molecular Weight | 1023.30 |